EUROAPI Aktie

 

Availability of the 2025 Universal Registration Document, including the Annual Financial Report...

Paris – December 16, 2025 - EUROAPI announced today that its main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend further the duration of their lock-up until December 18, 2026, subject to customary exceptions. This extension strengthens the stability of EUROAPI's shareholding structure throughout the execution of its FOCUS-27 plan....

Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders' meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective January 01, 2026, succeeding Rodolfo Savitzky....

BroadOak Fund VI completes first investment in Azure Biosystems; additional investments in Codis, VIDA Diagnostics, and Prognos HealthBETHESDA, Md.--(BUSINESS WIRE)--#BroadOak--BroadOak Capital Partners (“BroadOak”), a life-sciences focused investment and advisory firm, today announced multiple growth investments across its platform, highlighted by the first investment from BroadOak Fund VI, a growth equity financing in Azure Biosystems. This marks the third time over two decades that BroadOak has successfully partnered with the founders of Azure. BroadOak also formed and capitalized a special purpose vehicle to support Codis (formerly Particle Dynamics) in completing its acquisition of EUROAPI's Haverhill site. The firm's list of portfolio companies grew with recent investments into VIDA Diagnostics and Prognos Health. “BroadOak's partnership enables us to expand our platform's reach and deliver even greater insights to life sciences organizations striving to improve patient outcomes,” Sundee...

Pharmazeutische Wirkstoffe für Medikamente kommen vielfach aus Indien oder China. Euroapi produziert sie noch in Europa – muss im Frankfurter Industriepark Höchst aber eine Produktionsanlage einmotten....

The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe...

New global CDMO combines commercial spray drying and particle engineering technologies under one brand. Codis formed through integration of Particle Dynamics and the former EUROAPI site in Haverhill, UK Specializes in aqueous and solvent-based spray drying as well as amorphous solid......

New global CDMO combines commercial spray drying and particle engineering technologies under one brand. Codis formed through integration of Particle Dynamics and the former EUROAPI site in Haverhill, UK Specializes in aqueous and solvent-based spray drying as well as amorphous solid......

Paris – September 30, 2025 - EUROAPI today announces that, in line with best governance's practices, and following his appointment as Recipharm's Chief Financial Officer, effective October 1st, 2025, Rodolfo J. Savitzky will step down from his role as EUROAPI's Independent Director and Chair of the Audit Committee, effective December 31, 2025....

September 18, 2025 - EUROAPI's near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company's alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels....

Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI's website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. ...

Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a simultaneous closing to Particle Dynamics - a global leader in particle processing, delivery technologies, and finished dose manufacturing for the nutraceutical, consumer health, and pharmaceutical sectors....

Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors....

Paris – April 29, 2025 – EUROAPI's shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 21, 2025 at 10:30 a.m. (CET) at 15 bis, rue Traversière 75012 Paris. The notice of meeting was published at the French official legal announcement publication (BALO) on Wednesday April 16, 2025 and the convening notice (avis de convocation) was published in the Actu-juridique.fr, a French journal of legal notice, on April 28, 2025....

Paris – April 1, 2025 – EUROAPI announces the publication of its 2024 Universal Registration Document in ESEF format, filed with the French Autorité des marchés financiers (AMF) on April 1, 2025....